Neutrophilic Dermatoses: a Clinical Update

[1]  I. Majid,et al.  Sweet syndrome after Oxford‐AstraZeneca COVID‐19 vaccine (AZD1222) in an elderly female , 2021, Dermatologic therapy.

[2]  E. Clappier,et al.  UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome. , 2021, JAMA dermatology.

[3]  S. Guiducci,et al.  AstraZeneca (AZD1222) COVID‐19 vaccine‐associated adverse drug event: A case report , 2021, Journal of Medical Virology.

[4]  M. Sohail,et al.  Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine , 2021, BMJ Case Reports.

[5]  B. Kaffenberger,et al.  Health-related domains of quality of life in pyoderma gangrenosum: a qualitative analysis. , 2021, Journal of the American Academy of Dermatology.

[6]  S. Pédeboscq,et al.  Sweet syndrome induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine , 2021, Allergy.

[7]  K. Fogh,et al.  Pyoderma Gangrenosum: A Retrospective Study of Clinical Characteristics, Comorbidities, Response to Treatment and Mortality Related to Prednisone Dose , 2021, Acta dermato-venereologica.

[8]  Koichiro Nakamura,et al.  Normolipemic xanthomatized Sweet’s syndrome: A variant of Sweet’s syndrome with myelodysplastic syndrome , 2021, The Journal of dermatology.

[9]  J. Silverberg,et al.  The inpatient burden of pyoderma gangrenosum and associated comorbidities in children in the United States , 2021, Archives of Dermatological Research.

[10]  M. Shinohara,et al.  Treatment of pyoderma gangrenosum: A multicenter survey‐based study assessing satisfaction and quality of life , 2021, Dermatologic therapy.

[11]  A. Lallas,et al.  Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review , 2021, Dermatology practical & conceptual.

[12]  Daniel Q. Bach,et al.  Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review , 2020, Dermatologic therapy.

[13]  J. Mullikin,et al.  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2020, The New England journal of medicine.

[14]  M. Bagot,et al.  Acute myeloid leukemia and myelodysplastic syndrome-associated Sweet's syndrome: a comparative multicentric retrospective study of 39 patients. , 2020, Journal of the American Academy of Dermatology.

[15]  S. Langan,et al.  Pyoderma gangrenosum , 2020, Nature Reviews Disease Primers.

[16]  D. Takano,et al.  Case Report: Sweet Syndrome in Patients with Sporotrichosis: A 10-Case Series. , 2020, The American journal of tropical medicine and hygiene.

[17]  L. Dufrechou,et al.  Cryptococcoid Sweet Syndrome: A Clinical and Histologic Imitator of Cryptococcosis. , 2020, Actas dermo-sifiliograficas.

[18]  N. Conger,et al.  Sweet Syndrome in an Elderly Man With Well-Controlled Human Immunodeficiency Virus , 2020, Cureus.

[19]  K. Peris,et al.  Recalcitrant Sweet Syndrome successfully treated with adalimumab , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[20]  A. Garg,et al.  Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis. , 2020, Journal of the American Academy of Dermatology.

[21]  J. Silverberg,et al.  The inpatient burden and comorbidities of pyoderma gangrenosum in adults in the United States , 2020, Archives of Dermatological Research.

[22]  M. Ziv,et al.  Infliximab‐induced neutrophilic eccrine hidradenitis in a patient with hidradenitis suppurativa , 2020, Dermatologic therapy.

[23]  B. Ferhanoğlu,et al.  Coronavirus 19 presenting with atypical Sweet's syndrome , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  T. Hajar,et al.  Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum. , 2020, The Journal of investigative dermatology.

[25]  O. Karadag,et al.  Cancer incidence in Behçet’s disease , 2020, Irish Journal of Medical Science (1971 -).

[26]  Y. Braun-Moscovici,et al.  The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-Up. , 2020, The Israel Medical Association journal : IMAJ.

[27]  R. Haber,et al.  Risk of Malignancy in Histiocytoid Sweet Syndrome: A Systematic Review and Reappraisal. , 2020, Journal of the American Academy of Dermatology.

[28]  Yuwei Ding,et al.  Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy , 2020, Frontiers in Medicine.

[29]  E. Clappier,et al.  Next generation sequencing in myeloid neoplasm-associated Sweet's syndrome demonstrates clonal relation between malignant cells and skin-infiltrating neutrophils. , 2020, The Journal of investigative dermatology.

[30]  K. Raza,et al.  Epidemiology, morbidity and mortality in Behçet's disease: a cohort study using The Health Improvement Network (THIN). , 2020, Rheumatology.

[31]  Gabriel Yan,et al.  Histoplasmosis presenting with Sweet's syndrome. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  A. Ortega‐Loayza,et al.  Perioperative Management of Pyoderma Gangrenosum. , 2020, Journal of the American Academy of Dermatology.

[33]  Koichiro Nakamura,et al.  Guidelines for the treatment of skin and mucosal lesions in Behçet's disease: A secondary publication , 2020, The Journal of dermatology.

[34]  S. Vithoosan,et al.  A rare case of Sweet syndrome secondary to melioidosis , 2019, BMC dermatology.

[35]  Yeong-Wook Song,et al.  Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. , 2019, The New England journal of medicine.

[36]  Xin Wang,et al.  Risk of malignancy in Behcet disease , 2019, Medicine.

[37]  S. Mallet,et al.  Age‐specific characteristics of neutrophilic dermatoses and neutrophilic diseases in children , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[38]  D. Sène,et al.  Long‐Term Outcome of Ustekinumab Therapy for Behçet's Disease , 2019, Arthritis & rheumatology.

[39]  B. Kaffenberger,et al.  Characterisation and diagnosis of ulcers in inpatient dermatology consultation services: A multi‐centre study , 2019, International wound journal.

[40]  N. Maloney,et al.  Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review , 2019, Dermatologic therapy.

[41]  L. P. Samorano,et al.  Neutrophilic eccrine hidradenitis in a healthy Brazilian child , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[42]  C. Zdanski,et al.  Idiopathic, Refractory Sweet’s Syndrome Associated with Common Variable Immunodeficiency: a Case Report and Literature Review , 2019, Current Allergy and Asthma Reports.

[43]  G. Genovese,et al.  Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases , 2019, Front. Immunol..

[44]  Z. Shahid,et al.  Refractory Sweet Syndrome Treated with Anakinra , 2019, Cureus.

[45]  P. Panda,et al.  Ticagrelor induced neutrophilic eccrine hidradenitis: a unique adverse effect of a new antiplatelet drug , 2019, Postgraduate Medical Journal.

[46]  A. Marzano,et al.  Extracutaneous involvement of pyoderma gangrenosum , 2019, Archives of Dermatological Research.

[47]  A. Ortega‐Loayza,et al.  Insights Into the Pathogenesis of Sweet's Syndrome , 2019, Front. Immunol..

[48]  A. Amiot,et al.  Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study , 2019, Journal of the American Academy of Dermatology.

[49]  S. Benson,et al.  The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum , 2019, The British journal of dermatology.

[50]  A. Amedei,et al.  The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review , 2019, Rheumatology International.

[51]  Jyoti Panicker,et al.  Neutrophilic eccrine hidradenitis secondary to pegfilgrastim in a patient with synovial sarcoma , 2019, Clinical case reports.

[52]  L. Biard,et al.  Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients. , 2018, Clinical immunology.

[53]  C. Nelson,et al.  Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. , 2018, Journal of the American Academy of Dermatology.

[54]  C. Nelson,et al.  Neutrophilic dermatoses: Pyoderma gangrenosum and other bowel‐ and arthritis‐associated neutrophilic dermatoses , 2018, Journal of the American Academy of Dermatology.

[55]  V. Piguet,et al.  Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study , 2018, The British journal of dermatology.

[56]  Rui Zhang,et al.  Clonal neutrophil infiltrates in concurrent Sweet's syndrome and acute myeloid leukemia: A case report and literature review. , 2018, Cancer genetics.

[57]  J. Ehrchen,et al.  Sweet syndrome in association with enterobiasis , 2018, The Journal of dermatology.

[58]  T. Kanneganti,et al.  Cutting Edge: Dysregulated CARD9 Signaling in Neutrophils Drives Inflammation in a Mouse Model of Neutrophilic Dermatoses , 2018, The Journal of Immunology.

[59]  L. Atzori,et al.  Treatment of Sweet's syndrome in pregnancy , 2018, Dermatologic therapy.

[60]  W. Gulliver,et al.  Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials , 2018, The British journal of dermatology.

[61]  H. Maillard,et al.  Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients , 2018, The British journal of dermatology.

[62]  M. Menter,et al.  Histiocytoid Sweet syndrome successfully treated with etanercept , 2018, Proceedings.

[63]  R. Moots,et al.  2018 update of the EULAR recommendations for the management of Behçet’s syndrome , 2018, Annals of the rheumatic diseases.

[64]  Rosie Qin,et al.  Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts , 2018, JAMA dermatology.

[65]  L. French,et al.  Are neutrophilic dermatoses autoinflammatory disorders? , 2018, The British journal of dermatology.

[66]  C. Nelson,et al.  Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center , 2018, Journal of the American Academy of Dermatology.

[67]  A. Mostaghimi,et al.  Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—A retrospective analysis , 2018, Journal of the American Academy of Dermatology.

[68]  Claudia Fabiani,et al.  Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. , 2017, Clinical and experimental rheumatology.

[69]  Min Ji Kang,et al.  Cancer risk in patients with Behçet disease: A nationwide population‐based dynamic cohort study from Korea , 2017, Journal of the American Academy of Dermatology.

[70]  L. Cerroni,et al.  Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome , 2017, JAMA dermatology.

[71]  A. Ortega‐Loayza,et al.  Drug‐induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum , 2017, The British journal of dermatology.

[72]  J. Kaffenberger,et al.  Xanthomatized Neutrophilic Dermatosis in a Patient With Myelodysplastic Syndrome. , 2017, The American Journal of dermatopathology.

[73]  M. El-Khalawany,et al.  Clinicopathologic, immunophenotyping and cytogenetic analysis of Sweet syndrome in Egyptian patients with acute myeloid leukemia. , 2017, Pathology, research and practice.

[74]  E. Silvestri,et al.  Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study , 2017, Clinical Rheumatology.

[75]  J. Marcoval,et al.  Sweet syndrome: long‐term follow‐up of 138 patients , 2016, Clinical and experimental dermatology.

[76]  A. Khabir,et al.  Sweet's syndrome: a retrospective study of 90 cases from a tertiary care center , 2016, International journal of dermatology.

[77]  E. Alpsoy.  Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions , 2016, The Journal of dermatology.

[78]  D. Elder,et al.  FLT3 Inhibitor-Associated Neutrophilic Dermatoses. , 2016, JAMA dermatology.

[79]  C. Haioun,et al.  Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant , 2016, Medicine.

[80]  M. Wick,et al.  Cutaneous histiocytoid Sweet syndrome and its relationship to hematological diseases , 2016, Journal of cutaneous pathology.

[81]  Xuan Wang,et al.  Histiocytoid Sweet’s syndrome: A localized cutaneous proliferation of macrophages frequently associated with chronic myeloproliferative disease , 2015, European Journal of Dermatology.

[82]  H. Williams,et al.  Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial , 2015, BMJ : British Medical Journal.

[83]  A. Vitale,et al.  Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab , 2015, Clinical Rheumatology.

[84]  G. Hatemi,et al.  Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. , 2013, Rheumatology.

[85]  L. Gibson,et al.  Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. , 2013, Journal of the American Academy of Dermatology.

[86]  L. Le,et al.  FLT3 inhibitor-induced neutrophilic dermatosis. , 2013, Blood.

[87]  R. Nazarian,et al.  Subcutaneous Sweet syndrome in the setting of myeloid disorders: a case series and review of the literature. , 2013, Journal of the American Academy of Dermatology.

[88]  H. Dombret,et al.  Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients. , 2013, The Journal of investigative dermatology.

[89]  K. Shinkai,et al.  Etiology and Management of Pyoderma Gangrenosum , 2012, American Journal of Clinical Dermatology.

[90]  S. Langan,et al.  Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. , 2012, The Journal of investigative dermatology.

[91]  Heather K. Hamilton,et al.  Treatment of peristomal pyoderma gangrenosum with topical crushed dapsone. , 2011, Journal of drugs in dermatology : JDD.

[92]  D. Fanoni,et al.  Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil‐mediated skin diseases , 2010, Clinical and experimental immunology.

[93]  F. Shahram,et al.  Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double‐blind controlled trial , 2010, International journal of rheumatic diseases.

[94]  S. Chang,et al.  Generalized idiopathic neutrophilic eccrine hidradenitis in childhood , 2010, International journal of dermatology.

[95]  P. Picci,et al.  Synovial sarcoma , 2009, Cancer.

[96]  S. Gabriel,et al.  Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. , 2009, Arthritis and rheumatism.

[97]  J. Bolognia,et al.  Toxic erythema of chemotherapy: a useful clinical term. , 2008, Journal of the American Academy of Dermatology.

[98]  Philip R. Cohen.  Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis , 2007, Orphanet journal of rare diseases.

[99]  C. Magro,et al.  Clonality in the setting of Sweet’s syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease , 2007, Journal of cutaneous pathology.

[100]  B. Zelger,et al.  Acute Febrile Neutrophilic Dermatosis: A Histopathologic Study of 31 Cases With Review of Literature , 2007, The American Journal of dermatopathology.

[101]  A. Forbes,et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial , 2005, Gut.

[102]  F. Numan,et al.  Pulmonary artery aneurysms in Behçet syndrome. , 2004, The American journal of medicine.

[103]  R. Weenig,et al.  Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria , 2004, International journal of dermatology.

[104]  Fitzgeraldo A Sánchez Negrón,et al.  Pyoderma Gangrenosum: clinicopathological correlation and proposed diagnostic criteria , 2004, International journal of dermatology.

[105]  S. Yurdakul,et al.  Behçet syndrome , 2004, Current opinion in rheumatology.

[106]  Philip R. Cohen,et al.  Sweet's syndrome revisited: a review of disease concepts , 2003, International journal of dermatology.

[107]  A. Giasuddin,et al.  Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? , 1998, Journal of the American Academy of Dermatology.

[108]  J. Bourke,et al.  Sweet's syndrome and malignancy in the U.K. , 1997, The British journal of dermatology.

[109]  T. Nishikawa,et al.  Cutaneous vasculitis in Behçet's disease: a clinical and histopathologic study of 20 patients. , 1997, Journal of the American Academy of Dermatology.

[110]  S. Knowles,et al.  Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. , 1996, Journal of the American Academy of Dermatology.

[111]  T. McCalmont,et al.  Neutrophilic dermatoses in HIV infection. , 1994, Journal of the American Academy of Dermatology.

[112]  Z. Argényi,et al.  Acute neutrophilic dermatosis with myeloblastic infiltrate in a leukemia patient receiving all-trans-retinoic acid therapy. , 1994, Journal of the American Academy of Dermatology.

[113]  N. Cox,et al.  Sweet's syndrome associated with trans‐retinoic acid treatment in acute promyelocytic leukemia , 1994 .

[114]  G. Pawelec,et al.  Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease , 1993, British journal of haematology.

[115]  J. S. Taylor,et al.  Neutrophilic eccrine hidradenitis heralding the onset of acute myelogenous leukemia. , 1993, Archives of dermatology.

[116]  K. Thorisdottir,et al.  Neutrophilic eccrine hidradenitis. , 1993, Journal of the American Academy of Dermatology.

[117]  A. Venook,et al.  The Sweet syndrome during therapy with granulocyte colony-stimulating factor. , 1992, Annals of internal medicine.

[118]  M. Mochizuki,et al.  Human leukocyte antigen in Sweet's syndrome and its relationship to Behçet's disease. , 1988, Archives of dermatology.

[119]  R. Winkelmann,et al.  Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. , 1988, Journal of the American Academy of Dermatology.

[120]  H. N. Liu,et al.  Diagnostic criteria for Sweet's syndrome. , 1986, Cutis.

[121]  G. Firestein,et al.  Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease. , 1985, The American journal of medicine.

[122]  M. Mihm,et al.  Neutrophilic Eccrine Hidradenitis: A Distinctive Type of Neutrophilic Dermatosis Associated With Myelogenous Leukemia and Chemotherapy , 1982 .

[123]  A. Silman,et al.  [Criteria of diagnosis of Behcet's disease]. , 1975, La Tunisie medicale.

[124]  M. Farquhar,et al.  THE DEVELOPMENT OF NEUTROPHILIC POLYMORPHONUCLEAR LEUKOCYTES IN HUMAN BONE MARROW , 1971, The Journal of experimental medicine.

[125]  C. Whittle,et al.  RECURRENT NEUTROPHILIC DERMATOSIS OF THE FACE—A VARIANT OF SWEET'S SYNDROME , 1968, The British journal of dermatology.

[126]  R. Sweet.  AN ACUTE FEBRILE NEUTROPHTLIC DERMATOSTS. , 1964 .

[127]  L. Brunsting,et al.  PYODERMA (ECHTHYMA) GANGRENOSUM: CLINICAL AND EXPERIMENTAL OBSERVATIONS IN FIVE CASES OCCURRING IN ADULTS , 1930 .

[128]  Queiroz,et al.  The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[129]  Philip R. Cohen.  Neutrophilic Dermatoses , 2009, American journal of clinical dermatology.

[130]  E. Martínez,et al.  Idiopathic Palmoplantar Hidradenitis , 1997 .

[131]  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. , 1990, Lancet.